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Introduction: During pregnancy, an increase in insulin resistance occurs . GDM develops if there is inadequate insulin secretion to compensate insulin resistance. 
GDM increases the risk of pregnancy complications. Prospective randomized studies demonstrated that effective treatment of hyperglycemia in women with GDM can reduce 
2
adverse perinatal outcomes . The treatment is with diet, metformin or insulin. The disadvantages of insulin for pregnant women are: need to give injections, risk of hypoglycemia, risk of 
1
excessive weight gain, and cost . Theoretically, metformin is an alternative to insulin in the treatment of hyperglycemia during pregnancy. It does not induce hypoglycemia and it is not 
1
associated with increased weight gain. Also metformin reduces insulin resistance and hepatic gluconeogenesis, which could be beneficial for preservation of βcell function .
The number of studies reporting on the use of metformin in women with type 2 diabetes during pregnancy or GDM is small. They provide conflicting information about the safety of 
1
metformin use in type 2 diabetes or GDM pregnancies . 
Objective: The aim of the study was to compare maternal and neonatal outcomes in patients with gestational diabetes mellitus (GDM) treated with metformin versus those with insulin, 
or diet alone.
Matherial and methods: 62 women with GDM attending Outpatient department of University Clinic of Endocrinology Diabetes and Metabolic Disorders. 24 GDM women were 
treated with metformin, 21 with insulin, and 17 without pharmacological treatment, only on diet. All were with singleton pregnancies. 
Criteria for GDM were at least two out of three abnormally high plasma glucose value measurements in the 75 g OGTT (a fasting level ≥ 5,1, 1-hour level ≥ 10,0, 2-hour level ≥ 8,5 
3
mmol/l) . They were taught self-monitoring of plasma glucose, with instructions to measure fasting and postprandial values at 60 min after main meals at least four times a day during 
three consecutive days. The mode of treatment, based on self-monitored plasma glucose values, was determined within a week after starting monitoring. Metformin was given at a dose 
of 500 mg three times a day to a maximum of 2000 mg/day based on glycemic profile.
The outcome measures studied were glycemic control, maternal and neonatal outcome.
Statistical analysis: Statistical analyses were performed using SAS software for Windows, version 11.0. For analysis, t-test, Anova test, and Chi-square test were used. 
Results: 
Table 1. Maternal Characteristics at Baseline
 
D iet 
(N=17) 
M etform in 
(N=24) 
Insulin 
(N=21) 
M etfo
rm  vs. 
diet 
P  
M etfo
rm  vs. 
insuli 
P  
Diet 
vs. 
insu- 
lin 
P  
Age (years) 32,5±4,1 33,2±5,1 33±5,2 NS NS NS 
Pre- 
pregnancy 
BM I 
(kg/m
2
) 
27,6±7,7 29,1±5,7 29±5,0 NS NS NS 
W eight 
gain (kg) 
3,2±1,6 2,7±1,8 3,4±2,7 NS NS NS 
Gestational 
week at 
enrolm ent 
(wk) 
29,2±5,4 29±5,5 24,7±6,1 NS < 0,05 < 0,01 
Sm oking 
cigarettes 
(% ) 
2 (11,7% ) 3 (12,5% ) 2 (9,5% ) NS NS NS 
Fam iliar 
history for 
diabetes 
(% ) 
8 (47,1% ) 14 (58,3% ) 11 (52,4% ) NS NS NS 
 
Table 2 Maternal primary outcomes
Table 3. Neonatal primary outcomes
 
Diet 
(N=17) 
M etfor- 
min 
(N=24) 
Insulin 
(N=21) 
M etfor
m vs. 
diet 
P 
M etfo
rm vs. 
insu- 
lin 
P 
Diet 
vs. 
insulin 
P 
Birth weight 
(gr) 
3712±565 3452±482 3378±741 NS NS NS 
prematurity 0 2 (8,3%) 6 (28,6%) - NS - 
LGA (> 
2SD/% ) 
4 (23,5%) 4 (16,7%) 5 (23,8%) NS NS NS 
SGA (< 
2SD/% ) 
0 1 (4,2%) 2 (9,5%) NS NS NS 
Neonatal 
glycaemia 
(mean, %  
with 
hypoglycae-
mia) 
3,3±0,9 
(17,6%) 
2,6±0,8 
(33,3%) 
2,4±1,0 
(52,4%) 
< 0,05 
< 0,05 
NS 
< 0,05 
< 0,05 
< 0,05 
Apgar score 
at 5
’
 
8,4±0,5 8,3±0,6 8,1±0,7 NS NS NS 
 
LGA- large for gestational age, SGA- small for gestational age, 
SD- standard deviation;
Discussion: According to HbA1c, glycemic control in diet and metformin group were 
significantly better compared to insulin group. Also PPG was lower (without statistical 
4, 5
significance) in metformin group then in insulin group. As others conclude , metformin can 
be effective in controlling the GDM.
We found significantly fewer neonates with hypoglycemia in the metformin group 
compared with the insulin group (p = 0,04), although mean values did not differ statistically 
5
significant. These data are consistent with results of Tertti et al. , and observations in PCOS 
6
patients treated with metformin , but are inconsistent with the results obtained by Hellmuth et 
7
al.  In the latter study, increased rates of preeclampsia and perinatal loss were observed in 
mothers treated with metformin, but the groups were not well matched for age or body mass 
index. In this study, the groups were well matched and did not differ in the rates of 
preeclampsia, mode of delivery, apgar score at 5 minutes, birth weight, LGA and SGA. Also 
there was not perinatal loss. Few studies which included randomized 751 women with GDM 
into treatment with insulin or metformin, indicated that there were no serious adverse events 
associated with use of metformin. Even some PCOS studies, where metformin was used, 
8 5, 9
reported a reduction in spontaneous abortion in the first trimester . As others conclude , 
metformin is safe in GDM pregnancies. Also metformin is more acceptable to women with 
1
GDM then insulin . 
If metformin had any unanticipated adverse effect on fetal growth or well-being, there 
1
would be more iatrogenic preterm births . But, the frequency of preterm births was higher in 
the insulin group then in metformin group.
Conclusions: Maternal and neonatal outcomes were similar in metformin and insulin group.  
So, metformin appears to be effective and save in the treatment of GDM patients and may have 
its place as first line GDM therapy. However, further clinical long-term follow-up studies are 
needed to determine the role of metformin as an alternative treatment to insulin in GDM 
patients.
 
Diet 
(N=17) 
M etfor- 
min 
(N=24) 
Insulin 
(N=21) 
M etfo
rm vs. 
diet 
P 
M etfo
rm vs. 
insulin 
P 
Diet 
vs. 
insu- 
lin 
P 
HbA1c at 37 
g.w. (mean) 
4,5±0,9 5,3±0,7 6,1±1,3 < 0,05 < 0,05 < 0,01 
Fasting 
glycaemia 
mmol/l 
5,4±1,3 5,4±0,7 5,9±1,5 NS NS NS 
Postprandial 
glycaemia 
(PPG) 
mmol/l 
6,2±2,1 7,5±1,1 8,3±2,3 < 0,05 NS < 0,05 
preeclampsia 1 (5,9%) 2 (8,3%) 2 (9,5%) NS NS NS 
Gestational 
age at 
delivery (wk) 
39,1±2,2 38,7±1,6 37,3±2,4 NS < 0,05 < 0,05 
M ode of 
delivery 
-spontaneous 
- assisted 
- caesarean 
section 
 
7 (41,2%) 
1 (5,9%) 
9 (52,9%) 
 
10(41,7%) 
0 
14(58,3%) 
 
7 (33,3%) 
0 
14 (66,7%) 
 
NS 
NS 
NS 
 
NS 
NS 
NS 
 
NS 
NS 
NS 
 
Although mean birth weight in diet and 
metformin groups was higher, no statistically 
differences between the groups were 
observed (Table 3, Graphic 3). 
The incidence of neonatal hypoglycemia 
(s-gluc < 2.6 mmol/l) was statistically 
significant higher in insulin group compared 
with those treated with metformin or diet, but 
the difference between mean values between 
metformin and insulin groups did not reach 
statistical significance (Table 3, Graphic 4). 
There were no major complications or 
perinatal deaths in this study. One neonate had 
asphyxia, whose mother belongs to insulin 
group.
Mean glycosylated haemoglobin (HbA1c) at 37 gestation week was lower in diet and 
metformin groups than in insulin group (Table 2, Graphic 1). Mean postprandial 
glycaemia (PPG) statistically significant differed in diet from metformin group and in 
diet as to insulin group (Table 2, Graphic 2).
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